The high expression of CSN5 in CRC correlates with poor prognosis, suggesting its potential as a therapeutic target.139 CCL22 and CCL5 recruit these cells and not only suppress anti-tumor-immune responses but also create a protective niche that shields tumors from immune attacks, highlighting the potential of targeting these chemokines and their receptors to enhance anti-tumor immunity. The gene discussed is CCL22; the disease is neoplasm.